Timothy A. Springer - Jan 2, 2024 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Role: Director, 10%+ Owner
Signature: /s/ Matthew Bartholomae, Attorney-in-Fact for Timothy A. Springer
Stock symbol: RNAC
Transactions as of: Jan 2, 2024
Transactions value $: $0
Form type: 4
Date filed: 1/4/2024, 05:06 PM
Previous filing: Nov 15, 2023
Next filing: Mar 28, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RNAC	Common Stock	Award	$0	+178K	+2.44%	$0.00	7.47M	Jan 2, 2024	Direct	F1
holding	RNAC	Common Stock						29.9M	Jan 2, 2024	See Footnote	F2
holding	RNAC	Common Stock						86.4K	Jan 2, 2024	By wife

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RNAC	Stock Option (Right to Buy)	Award	$0	+228K		$0.00	228K	Jan 2, 2024	Common Stock	228K	$0.66	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in three equal annual installments so that the underlying shares will be fully vested on January 2, 2027.
F2	Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.
F3	This award will vest in 36 equal monthly installments, so that it shall be fully vested on the third anniversary of the date of grant.